Completed PHASE2 INTERVENTIONAL 9-arm NCT00074438

Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis

Randomized, Multifactorial, Double-blind, Parallel-group, Dose-ranging Study of the Efficacy and Safety of Rituximab (MabThera®/Rituxan®) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis

Sponsor: Genentech, Inc.

Conditions Rheumatoid Arthritis

Interventions corticosteroids methotrexate placebo rituximab

Updated 6 times since 2017 Last updated: May 7, 2013 Started: Jun 30, 2003 Primary completion: Sep 30, 2004 Completion: Jul 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00074438, this PHASE2 trial focuses on Rheumatoid Arthritis and remains completed. Sponsored by Genentech, Inc., it has been updated 6 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.
Roche Pharma AG

Data source: Genentech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.